Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics

Bibliography

• Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009;10:777-91
   PubMed Web of Science ®Google Scholar
• Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008;8:177-89
   PubMedGoogle Scholar
• Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat 2008;4:1059-71
   PubMedGoogle Scholar
• Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther 2006;8:208
   PubMed Web of Science ®Google Scholar
• Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007;146:726-34
   PubMed Web of Science ®Google Scholar
• Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Rev Rheumatol 2006;2:90-8
   Google Scholar
• Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82
   PubMed Web of Science ®Google Scholar
• Field MJ, Cox PJ, Stott E, Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006;103:17537-42
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-50
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
   PubMed Web of Science ®Google Scholar
• Kim L, Lipton S, Deodhar A. Pregabalin for fibromyalgia: some relief but no cure. Cleve Clin J Med 2009;76:255-61
   PubMed Web of Science ®Google Scholar
• Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49:706-15
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Pauer L, Danneskiold-Samsoe B, Jespersen A, Barret pregabalin for management of fibromyalgia (FM): a 14-week, randomized, double-blind, placebo-controlled, monotherapy trial. Ann Rheum Dis 2008;67:256
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
   PubMed Web of Science ®Google Scholar
• Bauer CS, Nieto-Rostro M, Rahman W, The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci 2009;29:4076-88
   PubMed Web of Science ®Google Scholar
• Hendrich J, Van Minh AT, Heblich F, Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 2008;105:3628-33
   PubMed Web of Science ®Google Scholar
• Takasu K, Honda M, Ono H, Tanabe M. Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury. Br J Pharmacol 2006;148:233-44
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Takasu K, Honda M, Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. Eur J Pharmacol 2007;556:69-74
   PubMed Web of Science ®Google Scholar
• Tanabe M, Takasu K, Kasuya N, Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol 2005;144:703-14
   PubMed Web of Science ®Google Scholar
• Kubota T, Fang J, Meltzer LT, Krueger JM. Pregabalin enhances nonrapid eye movement sleep. J Pharmacol Exp Ther 2001;299:1095-105
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005;28:187-93
   PubMed Web of Science ®Google Scholar
• Bliwise DL. Sleep in normal aging and dementia. Sleep 1993;16:40-81
   PubMed Web of Science ®Google Scholar
• Edwards RR, Haythornthwaite JA, Tella P, Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology 2006;104:1243-8
   PubMed Web of Science ®Google Scholar
• Kalso E, Simpson KH, Slappendel R, Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med 2007;5:39
   PubMed Web of Science ®Google Scholar